HIV Protease Inhibitors Do Not Cause the Accumulation of Prelamin A in PBMCs from Patients Receiving First Line Therapy: The ANRS EP45 "Aging" Study

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Perrin, Sophie ^a,b   Cremer, Jonathan ^a,b,f   Faucher, Olivia ^c   Reynes, Jacques ^d   Dellamonica, Pierre ^e   Micallef, Joëlle ^b   Solas, Caroline ^a,b   Lacarelle, Bruno ^a,b   Stretti, Charlotte ^a,b   Kaspi, Elise ^a,b   Robaglia Schlupp, Andrée ^a,b   Tamalet, Corine Nicolino Brunet Catherine ^a   Lévy, Nicolas ^a,b   Poizot Martin, Isabelle ^d   Cau, Pierre ^a,b   Roll, Patrice ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; BOVINE SERUM ALBUMIN; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIN A; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PRELAMIN A; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DETERMINATION; TREATMENT DURATION; VIRUS LOAD; WESTERN BLOTTING;

AGING; CARBAMATES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; LOPINAVIR; MALE; NUCLEAR PROTEINS; OLIGOPEPTIDES; PROTEIN PRECURSORS; PYRIDINES; RITONAVIR; SULFONAMIDES; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871826003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053035     Document Type: Article

References (67)

1. Lin F, Worman HJ, (1993) Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem. 268: 16321-16326.
2. Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ, (2006) Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev 86: 967-1008.
3. Dechat T, Pfleghaar K, Sengupta K, Shimi T, Shumaker DK, et al. (2008) Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev 22: 832-853.
4. Prokocimer M, Davidovich M, Nissim-Rafinia M, Wiesel-Motiuk N, Bar DZ, et al. (2009) Nuclear lamins: key regulators of nuclear structure and activities. J Cell Mol Med 13: 1059-1085.
5. Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M, (1992) Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci U S A 89: 3000-3004.
6. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, et al. (2002) Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A 99: 13049-13054.
7. Corrigan DP, Kuszczak D, Rusinol AE, Thewke DP, Hrycyna CA, et al. (2005) Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem J 387: 129-138.
8. Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, et al. (2002) Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 31: 94-99.
9. Andres V, Gonzalez JM, (2009) Role of A-type lamins in signaling, transcription, and chromatin organization. Journal of Cell Biology 187: 945-957.
10. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, et al. (1999) Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 21: 285-288.
11. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, et al. (1999) Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341: 1715-1724.
12. Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, et al. (2000) Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 9: 1453-1459.
13. De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, et al. (2002) Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 70: 726-736.
14. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, et al. (2000) LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24: 153-156.
15. Decaudain A, Vantyghem MC, Guerci B, Hecart AC, Auclair M, et al. (2007) New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 92: 4835-4844.
16. Dutour A, Roll P, Gaborit B, Courrier S, Alessi MC, et al. (2011) High prevalence of laminopathies among patients with metabolic syndrome. Hum Mol Genet 20: 3779-3786.
17. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423: 293-298.
18. Navarro CL, Cau P, Levy N, (2006) Molecular bases of progeroid syndromes. Hum Mol Genet 15Suppl 2: R151-161.
19. Hennekam RC, (2006) Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 140: 2603-2624.
20. Navarro CL, De Sandre-Giovannoli A, Bernard R, Boccaccio I, Boyer A, et al. (2004) Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 13: 2493-2503.
21. Navarro CL, Cadinanos J, De Sandre-Giovannoli A, Bernard R, Courrier S, et al. (2005) Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum Mol Genet 14: 1503-1513.
22. Scaffidi P, Misteli T, (2006) Lamin A-dependent nuclear defects in human aging. Science 312: 1059-1063.
23. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, et al. (2010) Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 121: 2200-2210.
24. Deeks SG, Phillips AN, (2009) HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. Bmj 338: a3172.
25. Deeks SG, (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
26. Garg A, (2011) Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 96: 3313-3325.
27. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, et al. (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53: 1120-1126.
28. Scott ES, O'Hare P, (2001) Fate of the inner nuclear membrane protein lamin B receptor and nuclear lamins in herpes simplex virus type 1 infection. J Virol 75: 8818-8830.
29. Muranyi W, Haas J, Wagner M, Krohne G, Koszinowski UH, (2002) Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science 297: 854-857.
30. de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, et al. (2001) Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294: 1105-1108.
31. Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, et al. (2007) HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A 104: 13432-13437.
32. Coffinier C, Hudon SE, Lee R, Farber EA, Nobumori C, et al. (2008) A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. Journal of Biological Chemistry 283: 9797-9804.
33. Liu Q, Kim DI, Syme J, LuValle P, Burke B, et al. (2010) Dynamics of lamin-A processing following precursor accumulation. PLoS ONE 5: e10874.
34. Lefevre C, Auclair M, Boccara F, Bastard JP, Capeau J, et al. (2010) Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arteriosclerosis, Thrombosis, and Vascular Biology 30: 2611-2620.
35. Miranda M, Chacon MR, Vidal F, Megia A, Richart C, et al. (2007) LMNA messenger RNA expression in highly active antiretroviral therapy-treated HIV-positive patients. J Acquir Immune Defic Syndr 46: 384-389.
36. Caron M, Auclair M, Donadille B, Bereziat V, Guerci B, et al. (2007) Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ 14: 1759-1767.
37. Bereziat V, Cervera P, Le Dour C, Verpont MC, Dumont S, et al. (2011) LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am J Pathol 179: 2443-2453.
38. Perrin S, Cremer J, Roll P, Faucher O, Menard A, et al. (2012) HIV-1 Infection and First Line ART Induced Differential Responses in Mitochondria from Blood Lymphocytes and Monocytes: The ANRS EP45 "Aging" Study. PLoS One 7: e41129.
39. Justesen US, Pedersen C, Klitgaard NA, (2003) Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 783: 491-500.
40. Colombo S, Guignard N, Marzolini C, Telenti A, Biollaz J, et al. (2004) Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 810: 25-34.
41. Marzolini C, Beguin A, Telenti A, Schreyer A, Buclin T, et al. (2002) Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. J Chromatogr B Analyt Technol Biomed Life Sci 774: 127-140.
42. Marsh KC, Eiden E, McDonald E, (1997) Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 704: 307-313.
43. van Heeswijk RP, Hoetelmans RM, Harms R, Meenhorst PL, Mulder JW, et al. (1998) Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 719: 159-168.
44. Quaranta S, Woloch C, Paccou A, Giocanti M, Solas C, et al. (2009) Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. Ther Drug Monit 31: 695-702.
45. Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, et al. (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14: 767-772.
46. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J, (2003) Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. Aids 17: 2437-2444.
47. Ghosh AK, Chapsal BD, Weber IT, Mitsuya H, (2008) Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc Chem Res 41: 78-86.
48. Hudon SE, Coffinier C, Michaelis S, Fong LG, Young SG, et al. (2008) HIV-protease inhibitors block the enzymatic activity of purified Ste24p. Biochemical and Biophysical Research Communications 374: 365-368.
49. Yeni (2010) Prise en charge médicale des personnes infectées par le VIH. ISBN: 978-2-11-008038-7. Available: http://www.sante.gouv.fr/rapport-2010-sur-la-prise-en-charge-medicale-des-personnes-infectees-par-le-vih-sous-la-direction-du-pr-patrick-yeni.html. Accessed: 2012 Jun 21.
50. Arab-Alameddine M, Decosterd LA, Buclin T, Telenti A, Csajka C (2011) Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opin Drug Metab Toxicol.
51. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, et al. (2010) Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clin Pharmacokinet 49: 17-45.
52. Ford J, Khoo SH, Back DJ, (2004) The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 54: 982-990.
53. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, et al. (2003) Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 19: 825-835.
54. Janneh O, Hartkoorn RC, Jones E, Owen A, Ward SA, et al. (2008) Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 155: 875-883.
55. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, et al. (2010) HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20: 112-120.
56. Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, et al. (2008) Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol 80: 766-771.
57. Oldfield V, Plosker GL, (2006) Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 66: 1275-1299.
58. Mukhopadhyay A, Wei B, Zullo SJ, Wood LV, Weiner H, (2002) In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome. Mitochondrion 1: 511-518.
59. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, et al. (2002) Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 3: 27-35.
60. Di Mascio M, Srinivasula S, Bhattacharjee A, Cheng L, Martiniova L, et al. (2009) Antiretroviral Tissue Kinetics: In Vivo Imaging Using Positron Emission Tomography. Antimicrob Agents Chemother 53: 4089-4095.
61. Cohen J, (2011) HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 334: 1614.
62. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al. (2011) Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission. Science Translational Medicine 3: 112re114-112re114.
63. Prot M, Heripret L, Cardot-Leccia N, Perrin C, Aouadi M, et al. (2006) Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother 50: 3998-4004.
64. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, et al. (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026-1031.
65. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, et al. (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50: 1378-1388.
66. Kudlow BA, Jameson SA, Kennedy BK, (2005) HIV protease inhibitors block adipocyte differentiation independently of lamin A/C. Aids 19: 1565-1573.
67. Boguslavsky RL, Stewart CL, Worman HJ, (2006) Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 15: 653-663.